The director of Apollo Cancer Centres in Hyderabad and founder of CURE Foundation honored for his contributions to cancer awareness and treatment
Sarin will focus on advancing scalable AI-driven platforms and strengthening the company’s global data science capabilities across healthcare and enterprise technology domains
We are contributing to the Indian pharmaceutical and laboratory sectors through advanced analytical instrumentation, automated liquid handling, and molecular biology solutions. Our technologies empower research and Quality Control (QC) by ensuring regulatory compliance and streamlined workflows…
Our Global Capability Center (GCC) in Bengaluru drives our major software development initiatives. Complementing this, our Bengaluru facility manufactures antibodies for research and diagnostics. Through these integrated technology and biotech operations, we are proud to contribute to India’s growth story in the life sciences sector.
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
Revenue from operations climbed 13% to Rs. 886.87 crore
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
Subscribe To Our Newsletter & Stay Updated
